Medical & Science Partners

ROY FIRST, MD
ROY FIRST, MD
Cour Pharmaceuticals

M. Roy First, M.D. was Vice President and Global Therapeutic Area Leader, Transplantation at Astellas Pharma Global Development, Inc. After graduating from medical school at the University of Witwatersrand in Johannesburg, South Africa, he moved to Chicago in 1972 to take the position of Renal Research Fellow at the Michael Reese Hospital.

In 1974, he was appointed Assistant Professor of Medicine in the Division of Nephrology at the University of Cincinnati, later becoming full Professor and Director of the Section of Transplantation, a position that he held until 2002, when he moved to Fujisawa (later Astellas). During his distinguished academic career, Dr. First has published more than 390 articles on transplantation, as well as 39 book chapters and two books. He is a past President of the American Society of Transplant Physicians (ASTP, subsequently AST) and has served on many United Network for Organ Sharing (UNOS) committees, including chairing the Organ Donation Committee, on the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA), as a reviewer for the National Institutes of Health (NIH), on the NIH Data Safety and Monitoring Board for Clinical Trials in Transplantation, and as a Councilor of the Transplantation Society. Dr. First has been on the editorial board of a number of journals including Transplantation, Transplantation Proceedings, Clinical Transplantation, the American Journal of Transplantation, and the Journal of the American Society of Nephrology. In 2013 he received the AST Lifetime Achievement Award.

KARI NADEAU, MD, PHD
KARI NADEAU, MD, PHD
Stanford University

Dr. Nadeau is one of the nation’s foremost experts in adult and pediatric allergy. She is the Director of the Nadeau Laboratory at Stanford and is an endowed professor under the Naddisy Family Foundation. Her medical research and clinical practice, in addition to her accomplishments in drug development in the biotech industry, have given her the tools to manage the complex web of asthma and allergy research.

Dr. Nadeau studies the mechanisms involved in allergies to better understand how to prevent and cure the disease. She has led many clinical research studies of allergic disorders. Her work has been recognized with numerous grants and awards, and her research is part of a prestigious Clinical and Translational Science Award from the National Institutes of Health (NIH). Dr. Nadeau has received honors and awards from the American Academy of Allergy, Asthma & Immunology; the American Lung Association; the Clinical Immunological Society; Food Allergy Research & Education (FARE); and the NIH. She has also been recognized with the U.S. Environmental Protection Agency’s STAR Grant Award.

Dr. Nadeau received her MD and PhD from Harvard Medical School. She completed a residency in pediatrics at Boston Children’s Hospital and a clinical fellowship in asthma and immunology at Stanford and University of California, San Francisco. She has been a faculty member at Lucile Packard Children’s Hospital Stanford since 2006.

CIARAN P. KELLY, MD
CIARAN P. KELLY, MD
Harvard Medical School

Dr Kelly is Professor of Medicine at Harvard Medical School and Chief of the Herrman L. Blumgart Internal Medicine Firm, Director of Gastroenterology Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts. Dr. Kelly has longstanding clinical and research interests in intestinal infection and inflammation. He is the author of more than 150 clinical and basic research book chapters, invited reviews, and peer-reviewed publications appearing in such journals as Infection & Immunity, American Journal of Physiology, Gastroenterology, Journal of Biological Chemistry, Journal of Clinical Investigation, The Lancet and New England Journal of Medicine. For over 20 years Dr Kelly has committed himself to finding new medical solutions to C. difficile infection, inflammatory bowel disease and Celiac Disease. He heads clinical, research and educational programs in celiac disease as Medical Director of the Celiac Center at Harvard.

STEPHEN D. MILLER, PHD
STEPHEN D. MILLER, PHD
Northwestern University

Dr. Miller is internationally known for his research on pathogenesis and regulation of autoimmune diseases and is co-inventor of the Cour toleragenic immune modifiying particle technology platform. Dr. Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago. He is a consultant to a number of biotechnology and pharmaceutical companies, having assisted in the development of three new chemical entities from proof of concept through to Phase 3 testing. He has served or currently serves on grant review panels for the National Institute of Health, the National MS Society, the Immune Tolerance Network and the Juvenile Diabetes Research Foundation and on the editorial boards of multiple journals. He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981.

His work has significantly enhanced the understanding of immune inflammatory processes underlying chronic autoimmune disease employing animal models of multiple sclerosis (MS) and Type 1 diabetes (T1D). He was the first to describe the contribution of epitope spreading to endogenous self tissue antigens in mediating chronic CNS damage in both autoimmune [experimental autoimmune encephalomyelitis (EAE) and Theiler’s virus-induced demyelinating disease models of MS and more recently in T1D in NOD mice. He is also noted for his work describing the cellular and molecular mechanisms underlying initiation and progression of autoimmunity by infection-induced molecular mimicry. The most widely known aspect of Dr. Miller’s scientific career has focused on the study of the cellular and molecular mechanisms underlying treatment of established T cell-mediated autoimmune diseases using antigen-specific therapies – including regulatory T cells (Tregs), short-term co-stimulatory molecule blockade strategies, and induction of immune tolerance to autoantigens induced via i.v. injection of apoptotic antigen-pulsed leukocytes and nanoparticles.

LONNIE D. SHEA, PHD
LONNIE D. SHEA, PHD
University of Michigan

Lonnie D. Shea is a world leading biomaterial scientist and co-inventor of the Cour nanoparticle technology platform. He currently serves as a Professor in the Department of Chemical and Biological Engineering at University of Michigan. He received his BS and MS degrees in chemical engineering at Case Western Reserve University, and his PhD in Chemical Engineering and Scientific Computing while working with Jennifer Linderman at the University of Michigan, and was a postdoctoral fellow with David Mooney in the Department of Biologic and Materials Science in the Dental School at the University of Michigan.

Prior to his current role, he was on the faculty at Northwestern University where he established a research group working at the interface of tissue engineering, gene therapy, and drug delivery. He received an NSF CAREER Award in 2000, which helped start the work on developing new technologies based on combining biomaterials and gene/drug delivery. In addition, the Shea Lab works at the interface of regenerative medicine, biomaterials, and gene and drug delivery. The central theme for the various projects is creating synthetic environments which can be employed to molecularly dissect tissue formation or promote regeneration. These systems are being applied to clinical problems such as ovarian follicle maturation for treating infertility, islet transplantation for diabetes therapies, nerve regeneration for treating paralysis, and most recently, cancer diagnostics. Dr. Shea has received funding from NIH, NSF, and multiple foundations, and has published in excess of 120 manuscripts on his research. Dr. Shea is a fellow of the American Institute of Medical and Biological Engineering, and is a member of the editorial boards for Molecular Therapy, Biotechnology and Bioengineering, and Drug Delivery and Translational Research.